After the Bell
Before the Bell
Jim Cramer's Daily Booyah
Winners & Losers
Irish pharmaceuticals company Shire said on Friday it had arranged to hand its Dermagraft skin substitute to Organogenesis and take a $650 million loss on the disposal, which unwinds a major part of an acquisition it made less than three years ago.
Markets edged higher as some stocks jumped on deal making, with key retailer results to be closely watched this week.
Shire's purchase of ViroPharma is a signal of deals and higher prices ahead, says Jason Kolbert, Sr. Research Analyst at the Maxim Group.
Upbeat economic data from China prints ahead of the week's trading, while Viropharma and Transocean attract investors' attention.
©1996-2016 TheStreet, Inc. All rights reserved.
Action Alerts PLUS is a registered trademark of TheStreet, Inc.